Monday, July 15, 2024

Viatris Achieves First BSI Certification for Antimicrobial Resistance Risk in India

Similar articles

Viatris has received notification that its facility in Aurangabad, India, has attained certification from the British Standards Institution (BSI) for meeting a newly established industry standard focused on minimized risk of antimicrobial resistance (AMR). Facilitated by BSI for the AMR Industry Alliance, comprising over 100 companies and associations within the life sciences sector, this certification aims to encourage drug manufacturers and supply chain stakeholders to prioritize sustainable antibiotic production.

Sanjeev Sethi, Viatris’ Chief Operations Officer, expressed pride in being the first pharmaceutical site in India to achieve this significant certification. He credited the achievement to the dedication of the cross-functional team in implementing sustainable systems and processes to promote responsible antibiotic manufacturing.

Steve Brooks, Advisor and Manufacturing Work Group Lead at AMR Industry Alliance commended Viatris for its leadership and commitment to addressing global antimicrobial resistance challenges. He noted Viatris’ active contribution to the alliance’s efforts in providing sustainable solutions to combat AMR while prioritizing environmental stewardship.

Viatris’ Landmark Achievement in Antibiotic Manufacturing Certification in India

Antimicrobial resistance poses a substantial and multifaceted challenge to public health and global socioeconomic well-being. Its impact extends far beyond the realm of healthcare, influencing various sectors and economies worldwide. The alarming rise of antimicrobial resistance threatens to undermine decades of medical progress and significantly elevate mortality rates on a global scale.

Recent epidemiological data underscores the gravity of the AMR crisis. In 2019 alone, antibiotic-resistant bacterial infections were directly implicated in over 1.2 million deaths worldwide. This staggering toll reflects the growing ineffectiveness of conventional antimicrobial treatments against resilient bacterial strains. Moreover, the prevalence of AMR is not limited to any specific geographic region or demographic group, making it a truly global health concern. Compounding the urgency of addressing AMR is its projected trajectory. Without concerted and decisive intervention, experts warn that AMR could surpass cancer as a leading cause of death by the year 2050. This ominous forecast underscores the imperative for immediate action to stem the tide of antimicrobial resistance and prevent its catastrophic consequences.

The multifaceted nature of AMR demands a comprehensive and coordinated response from governments, healthcare systems, pharmaceutical companies, and other stakeholders. Efforts to combat AMR must encompass a spectrum of strategies, including enhanced surveillance, judicious antimicrobial use, robust infection prevention and control measures, and the development of novel therapeutics. Furthermore, addressing the underlying drivers of AMR, such as overuse and misuse of antibiotics in human and animal health, agricultural practices, and environmental contamination, is paramount to curbing its proliferation. Collaborative initiatives at the local, national, and international levels are essential to fostering innovation, promoting responsible antimicrobial stewardship, and safeguarding the efficacy of existing treatment options.

Antimicrobial Resistance

Viatris Leading the Charge in Global Antimicrobial Resistance Mitigation Efforts

In this context, the certification of Viatris’ Aurangabad facility by the British Standards Institution (BSI) for its adherence to the Minimized Risk of Antimicrobial resistance standard represents a significant milestone in the ongoing battle against AMR. By prioritizing sustainable antibiotic production practices, Viatris demonstrates its commitment to mitigating the spread of antimicrobial resistance and advancing global public health goals.

Viatris remains steadfast in its commitment to combating AMR through initiatives focused on enhancing access, stewardship, and responsible manufacturing practices. Access to a diverse range of high-quality antimicrobials and timely treatment are essential elements in mitigating the rise of AMR. With approximately 90 antimicrobials in its global portfolio, including antibiotics effective against resistant bacteria, Viatris plays a crucial role in providing solutions to address this global health threat.

You can follow our news on our Telegram and LinkedIn accounts.

As a founding member of the AMR Industry Alliance (AMRIA), Viatris actively collaborates with industry peers to advance initiatives aimed at combating AMR comprehensively. Through these collective efforts, Viatris and its partners are dedicated to fostering sustainable practices and promoting responsible antibiotic use to safeguard public health.

 

Resource: Newsroom Viatris, February 20, 2024

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article